FDA
-
-
-
-
-
-
-
Revolution Medicines publishes pancreatic cancer trial data in NEJM
-
-
-
-
-
-
-
Revolution (RVMD) PT Raised to $147 at Leerink Partners
-
-
-
-
-
-
-
Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress
-
-
-
-
-
-
-
Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib
-
-
-
-
-
-
-
Barbara Weber, M.D., Elected to ITM Supervisory Board
-
-
-
-
-
-
-
Revolution Medicines Reports First Quarter 2022 Financial Results and Update on Corporate Progress
-
-
-
324,764 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

